An innovative mechanism of action

With specific dual-action binding, EYLEA® blocks all known VEGF-A isoforms and PGF1,2

EYLEA Mechanism of Action

a VEGF suppression with EYLEA was assessed in a study in 27 nAMD patients.

nAMD, neovascular age-related macular degeneration; PGF, placental growth factor; VEGF, vascular endothelial growth factor.

References

  1. EYLEA® (aflibercept solution for injection) Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG; July 2018.
  2. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis. 2012;15(2):171-185.
  3. Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158(3):532-536.
  4. Stewart MW. Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug. Br J Ophthalmol. 2012;96(9):1157-1158.
  5. Muether PS, Hermann MM, Dröge K, et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993.